Pemvidutide (ALT-801)

1. Overview

Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist peptide developed by Altimmune, Inc. for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as non-alcoholic steatohepatitis or NASH) [8][9]. It belongs to an emerging class of multi-receptor agonist peptides that extend the therapeutic paradigm beyond pure GLP-1 receptor agonists (such as semaglutide and liraglutide) by incorporating glucagon receptor co-agonism to address metabolic pathways not reached by GLP-1 signaling alone.

The dual agonist concept was first validated preclinically by Day et al. (2009) and Pocai et al. (2009), who independently demonstrated that co-agonism at GLP-1 and glucagon receptors produced synergistic metabolic benefits exceeding those of either receptor alone [1][2]. The rationale is grounded in the complementary metabolic effects of the two receptors:

GLP-1 receptor agonism provides:

• Appetite suppression via hypothalamic satiety circuits
• Delayed gastric emptying (promoting early satiety)
• Enhanced glucose-dependent insulin secretion
• Reduced glucagon secretion during hyperglycemia

Glucagon receptor agonism adds:

• Increased hepatic energy expenditure through lipid oxidation
• Enhanced thermogenesis
• Increased lipolysis
• Direct reduction of hepatic lipid content (critical for MASH)

The inclusion of glucagon agonism was initially viewed as counterintuitive, since glucagon raises blood glucose -- an undesirable effect in diabetic patients. However, the GLP-1 component's insulin-sensitizing and glucose-lowering effects counterbalance glucagon's hyperglycemic action, while the glucagon component's effects on energy expenditure and hepatic fat metabolism provide benefits that GLP-1 alone cannot achieve [1][3][6].

Pemvidutide has completed Phase 2 trials in both obesity (MOMENTUM) and MASH (IMPACT), with results demonstrating clinically meaningful weight loss and substantial liver fat reduction [8][9]. In January 2026, the FDA granted Breakthrough Therapy Designation (BTD) for pemvidutide in MASH, and Altimmune is finalizing plans to initiate a registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis in 2026, following a productive end-of-Phase 2 meeting with the FDA. Additional Phase 2 trials in alcohol use disorder (RECLAIM) and alcohol-associated liver disease (RESTORE) are ongoing.

Type

Dual GLP-1/glucagon receptor agonist peptide

Developer

Altimmune, Inc.

Other Designation

ALT-801

Receptor Targets

GLP-1 receptor and glucagon receptor (GCGR)

Route

Subcutaneous injection (once weekly)

Clinical Stage

Phase 2 completed; Phase 3 planned for 2026 (MASH)

FDA Status

Investigational; Breakthrough Therapy Designation for MASH (January 2026)

Primary Indications

Obesity, MASH (formerly NASH)

Key Differentiator

Glucagon component enhances liver fat reduction and energy expenditure

2. Mechanism of Action

GLP-1 Receptor Pathway

Pemvidutide activates the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in pancreatic beta cells, hypothalamus, brainstem, gastrointestinal tract, and cardiovascular system [11]. GLP-1R activation produces:

• Central appetite suppression: GLP-1R activation in the arcuate nucleus, paraventricular nucleus, and area postrema of the brain reduces hunger and promotes satiety
• Gastric emptying delay: Vagal afferent GLP-1R signaling slows gastric motility, prolonging postprandial fullness
• Insulin potentiation: Beta cell GLP-1R activation augments glucose-dependent insulin secretion
• Glucagon suppression: In hyperglycemia, GLP-1R activation reduces inappropriate alpha cell glucagon secretion

Glucagon Receptor Pathway

Pemvidutide also activates the glucagon receptor (GCGR), a class B GPCR expressed primarily in the liver, with lower expression in kidney, heart, and adipose tissue [1][3]. GCGR activation produces:

• Hepatic lipid oxidation: Glucagon signaling increases beta-oxidation of fatty acids in the liver, directly reducing hepatic steatosis -- the hallmark pathology of MASH [5]
• Energy expenditure: Glucagon increases metabolic rate through enhanced thermogenesis and metabolic cycling
• Lipolysis: Glucagon promotes adipose tissue lipolysis, mobilizing fat stores for energy utilization
• Amino acid catabolism: Glucagon promotes hepatic ureagenesis and amino acid oxidation

Synergistic Dual Agonism

The two pathways are complementary [1][2][3]:

• GLP-1 drives weight loss primarily through reduced energy intake (appetite suppression, delayed gastric emptying)
• Glucagon drives weight loss primarily through increased energy expenditure (hepatic thermogenesis, lipid oxidation)
• GLP-1's glucose-lowering effects counterbalance glucagon's hyperglycemic potential
• Glucagon's hepatic lipid-clearing effects address MASH pathology beyond what GLP-1 alone achieves

This "metabolic balance" between the two components is the defining feature of the dual agonist approach and explains why pemvidutide and related compounds achieve substantial liver fat reduction alongside body weight loss [1][6].

3. Clinical Development

Phase 1b Results

In a 12-week Phase 1b trial, pemvidutide produced dose-dependent weight loss of up to 9.1% with rapid liver fat reduction of up to 66% from baseline [10]. The liver fat reduction was notably rapid, occurring within the first weeks of treatment and exceeding the rate seen with pure GLP-1 agonists, consistent with the glucagon component's direct hepatic lipid oxidation effect.

MOMENTUM Trial (Phase 2 Obesity)

The Phase 2 MOMENTUM trial enrolled 391 adults with obesity or overweight with weight-related comorbidities, randomized to pemvidutide 1.2 mg, 1.8 mg, or 2.4 mg weekly versus placebo for 48 weeks [8]:

• Body weight loss at 48 weeks: 15.6% at 2.4 mg vs. 2.2% placebo
• Liver fat reduction: Up to 78.6% at the 2.4 mg dose
• Waist circumference: Significant reductions across all dose groups
• Metabolic parameters: Improvements in lipids, blood pressure, and glycemic markers
• Tolerability: Predominantly gastrointestinal adverse events (nausea, vomiting, diarrhea), generally mild-to-moderate and decreasing over time with dose escalation

IMPACT Trial (Phase 2b MASH)

The IMPACT trial evaluated pemvidutide in adults with biopsy-confirmed MASH [9]. At 24 weeks, results demonstrated significant reduction in liver fat content measured by MRI-PDFF, improvements in fibrosis biomarkers, and reduction in hepatic inflammation markers. At 48 weeks (December 2025 topline data), continued treatment resulted in statistically significant improvements in Enhanced Liver Fibrosis (ELF) score and Liver Stiffness Measurement (LSM) versus placebo, with additional reductions from week 24 across both dose levels, supporting ongoing antifibrotic activity. Patients receiving the 1.8 mg dose achieved further weight loss at 48 weeks with no evidence of plateauing, and pemvidutide maintained a favorable tolerability profile with a lower discontinuation rate due to adverse events compared with placebo.

FDA Breakthrough Therapy Designation (January 2026)

On January 5, 2026, the FDA granted Breakthrough Therapy Designation for pemvidutide for the treatment of MASH. This designation is based on the IMPACT trial data and reflects the FDA's recognition of pemvidutide's potential to address a serious condition with significant unmet need. Altimmune completed a productive end-of-Phase 2 meeting with the FDA, resulting in alignment on parameters for a registrational Phase 3 trial of pemvidutide in MASH patients with moderate to advanced liver fibrosis. The Phase 3 program is expected to initiate in 2026.

Additional Development Programs (2025-2026)

Altimmune has expanded pemvidutide's clinical pipeline into liver-related conditions beyond MASH. The RECLAIM Phase 2 trial evaluating pemvidutide in alcohol use disorder (AUD) was initiated in May 2025, with enrollment completed early and topline data expected in Q3 2026. The RESTORE Phase 2 trial in alcohol-associated liver disease (ALD) was initiated in July 2025

4. Comparison with Other Multi-Agonists

vs. Tirzepatide (GIP/GLP-1)

Tirzepatide targets GIP and GLP-1 receptors (not glucagon). Its mechanism produces potent weight loss (up to 22.5% in Phase 3) primarily through appetite suppression and enhanced insulin sensitivity. Pemvidutide's glucagon component may provide superior liver fat reduction, positioning it for MASH applications.

vs. Retatrutide (GIP/GLP-1/Glucagon)

Retatrutide is a triple agonist (GIP, GLP-1, and glucagon) that achieved 24.2% weight loss at 48 weeks in Phase 2. Pemvidutide's 15.6% at 48 weeks is lower, but the two compounds have different receptor activation ratios and may differ in liver-specific effects.

vs. Mazdutide (GLP-1/Glucagon)

Mazdutide is a fellow GLP-1/glucagon dual agonist developed by Innovent Biologics/Eli Lilly for the Chinese market, approved by NMPA in 2024. Both compounds share the dual agonist mechanism but differ in molecular structure and clinical positioning.

5. Clinical Evidence Summary

6. Dosing in Research

7. Safety and Side Effects

The most common adverse effects in pemvidutide clinical trials have been gastrointestinal in nature, consistent with the class effects of GLP-1 receptor agonists [8]:

• Nausea: The most frequent adverse event; typically mild-to-moderate, decreasing with continued dosing
• Vomiting: Less frequent than nausea; improved with dose escalation protocols
• Diarrhea: Mild-to-moderate; generally transient
• Decreased appetite: Expected pharmacological effect rather than adverse event

The glucagon component raises specific safety considerations:

• Glucose homeostasis: Glucagon receptor agonism inherently raises hepatic glucose output. In pemvidutide, this effect is counterbalanced by the GLP-1 component's glucose-lowering properties. Clinical data have not shown clinically significant hyperglycemia in non-diabetic populations
• Heart rate: Both GLP-1 and glucagon can increase heart rate; clinical monitoring is important
• Lean mass preservation: Glucagon's catabolic effects could theoretically accelerate lean mass loss during weight reduction; this requires monitoring in longer-term studies

8. Pharmacokinetics

Dual Receptor Agonist Design

Pemvidutide is a peptide-based dual agonist designed for once-weekly subcutaneous administration [8][10]. The pharmacokinetic profile supports sustained receptor engagement at both GLP-1R and GCGR throughout the dosing interval.

Absorption: Following subcutaneous injection, pemvidutide is absorbed with pharmacokinetics supporting once-weekly dosing. The Phase 1b study confirmed dose-proportional exposure across the tested dose range [10].

Half-life: Pemvidutide's half-life supports once-weekly administration, consistent with other peptide-based incretin agonists that achieve extended half-lives through albumin binding, acylation, or structural modifications that reduce renal clearance. The exact terminal half-life has not been publicly disclosed but is functionally in the range of days based on the weekly dosing interval.

Distribution: As a dual receptor agonist, pemvidutide distributes to tissues expressing both GLP-1R (pancreas, hypothalamus, brainstem, GI tract, cardiovascular system) and GCGR (liver, kidney, heart, adipose tissue) [11]. The hepatic GCGR engagement is particularly relevant for the liver fat reduction effects observed in clinical trials.

Dose escalation pharmacokinetics: Pemvidutide uses a dose escalation protocol (starting at lower doses and increasing over weeks) to improve GI tolerability [8]. This approach allows GLP-1R-mediated GI effects to attenuate through receptor adaptation while building toward the target maintenance dose.

GLP-1 vs. Glucagon Receptor Activation Balance

The pharmacokinetic design of pemvidutide maintains a specific ratio of GLP-1R to GCGR activation that achieves the desired metabolic balance [1][3]:

• GLP-1R component provides sustained appetite suppression and glucose-lowering throughout the dosing interval
• GCGR component provides sustained hepatic lipid oxidation and thermogenesis
• Glucose homeostasis: The GLP-1R activation must be sufficient to counterbalance GCGR-mediated hepatic glucose output at all points in the pharmacokinetic curve

9. Dose-Response Relationships

Weight Loss Dose-Response (MOMENTUM Trial)

The Phase 2 MOMENTUM trial established a clear dose-response relationship for body weight loss at 48 weeks [8]:

• Placebo: 2.2% weight loss
• 1.2 mg weekly: Moderate weight loss (exact value below 2.4 mg response)
• 1.8 mg weekly: Intermediate weight loss between 1.2 mg and 2.4 mg groups
• 2.4 mg weekly: 15.6% mean body weight loss -- the maximum dose tested and most efficacious

Weight loss was progressive throughout the 48-week treatment period, with curves that had not fully plateaued, suggesting potential for further weight reduction with extended treatment.

Liver Fat Dose-Response

Liver fat reduction showed a particularly striking dose-response in the MOMENTUM trial [8]:

• Phase 1b (12 weeks): Up to 66% liver fat reduction at the highest dose [10]
• MOMENTUM (48 weeks): Up to 78.6% liver fat reduction at the 2.4 mg dose [8]

The liver fat reduction was notably rapid in onset, occurring within the first weeks of treatment -- faster than would be expected from weight loss alone. This early hepatic response is attributed to the glucagon component's direct stimulation of hepatic fatty acid beta-oxidation [5].

MASH-Specific Dose-Response (IMPACT Trial)

In the IMPACT trial targeting biopsy-confirmed MASH, pemvidutide demonstrated [9]:

• Significant reduction in liver fat content measured by MRI-PDFF at both 1.8 mg and 2.4 mg doses
• Improvements in fibrosis biomarkers
• Reduction in hepatic inflammation markers
• Weight loss consistent with MOMENTUM findings

The dual mechanism (GLP-1 appetite suppression plus glucagon hepatic lipid oxidation) produces liver fat reduction exceeding that expected from weight loss alone, a phenomenon attributed to glucagon's direct hepatic metabolic effects [5][7].

10. Comparative Effectiveness

vs. Semaglutide 2.4 mg (Wegovy)

| Parameter | Pemvidutide 2.4 mg | Semaglutide 2.4 mg | |---|---|---| | Mechanism | Dual GLP-1/glucagon | Pure GLP-1 | | Weight loss | 15.6% at 48 weeks | ~15-17% at 68 weeks (STEP trials) | | Liver fat reduction | 78.6% at 48 weeks | ~30-40% (estimated from clinical data) | | MASH indication | Phase 2 (IMPACT trial) | Phase 2 (ongoing studies) | | GI side effects | GI AEs (class effect) | GI AEs (class effect) | | Regulatory status | Investigational (Phase 2) | FDA-approved for obesity |

Pemvidutide's glucagon component provides substantially greater liver fat reduction compared to pure GLP-1 agonists, positioning it as potentially superior for patients with co-existing obesity and MASH [8][9]. Weight loss magnitude is broadly similar at comparable timepoints, though direct head-to-head data are not available.

vs. Survodutide (BI 456906, Boehringer Ingelheim)

Survodutide is another GLP-1/glucagon dual agonist in clinical development for obesity and MASH:

• Both share the dual agonist mechanism targeting the same two receptors
• Survodutide achieved up to 19% weight loss at 46 weeks in Phase 2 obesity studies
• Survodutide demonstrated significant MASH resolution and fibrosis improvement in Phase 2
• Both demonstrate superior liver fat reduction compared to pure GLP-1 agonists
• The two compounds differ in molecular structure, receptor activation ratios, and dosing regimens

vs. Tirzepatide (Mounjaro/Zepbound)

| Parameter | Pemvidutide | Tirzepatide | |---|---|---| | Receptor targets | GLP-1 + Glucagon | GLP-1 + GIP | | Weight loss | 15.6% at 48 weeks | Up to 22.5% at 72 weeks (SURMOUNT-1) | | Liver fat reduction | 78.6% | ~37-53% (SYNERGY-NASH) | | Hepatic mechanism | Direct glucagon-driven lipid oxidation | Indirect (via weight loss and insulin sensitization) | | MASH positioning | Strong (dual mechanism) | Moderate (primarily weight-driven) |

Tirzepatide achieves greater overall weight loss through GIP/GLP-1 synergy, but pemvidutide's glucagon component may provide superior liver-specific fat reduction, making it more suitable for MASH-predominant patient populations [6][8].

vs. Retatrutide (LY3437943, Triple Agonist)

Retatrutide targets GIP, GLP-1, and glucagon receptors (triple agonist) and achieved 24.2% weight loss at 48 weeks in Phase 2. It combines the advantages of both GIP (from tirzepatide) and glucagon (from pemvidutide/survodutide) agonism. Pemvidutide's 15.6% at the same timepoint is lower, but the simpler dual agonist design may offer advantages in receptor ratio optimization and safety predictability.

11. Enhanced Safety Profile

Gastrointestinal Tolerability

GI adverse events (nausea, vomiting, diarrhea) are the most common side effects, consistent with the GLP-1 agonist class [8]. Management strategies include:

• Dose escalation: Gradual titration from lower starting doses reduces GI intolerance during GLP-1R adaptation
• Temporal pattern: GI AEs are most prevalent during dose escalation and typically diminish with continued treatment
• Severity: Generally mild-to-moderate; severe GI AEs leading to discontinuation were uncommon in the MOMENTUM trial

Glucose Homeostasis

The glucagon component's hyperglycemic potential is the primary safety consideration unique to dual agonists [1][3]:

• GLP-1 counterbalance: The GLP-1 component's insulin-potentiating and glucagon-suppressing effects offset GCGR-mediated hepatic glucose output
• Clinical evidence: No clinically significant hyperglycemia was observed in non-diabetic populations in the MOMENTUM trial [8]
• Diabetic patients: Glucose monitoring is particularly important, as the balance between GLP-1-mediated glucose lowering and glucagon-mediated glucose raising may differ depending on beta cell function

Cardiovascular Monitoring

Both GLP-1 and glucagon can increase heart rate through direct cardiac and sympathetic nervous system effects [8]:

• Heart rate increases of 2-5 bpm have been observed with GLP-1 agonists
• Glucagon's chronotropic effect may add to this
• Clinical monitoring of heart rate is appropriate, particularly in patients with pre-existing cardiac conditions

Lean Mass Preservation

Glucagon's catabolic effects (amino acid oxidation, ureagenesis) could theoretically accelerate lean mass loss during caloric deficit [3][6]:

• This is a theoretical concern for all weight loss agents but may be amplified by glucagon agonism
• Body composition data from longer-term studies will be important to characterize the lean-to-fat mass loss ratio
• Resistance exercise recommendations may be particularly important for patients on dual agonist therapy

Hepatic Safety

Despite glucagon's acute effects on hepatic glucose output, the net hepatic effect of pemvidutide appears protective [5][9]:

• Massive liver fat reduction (up to 78.6%) indicates beneficial hepatic metabolic reprogramming
• Improvements in fibrosis biomarkers suggest anti-fibrotic effects
• No hepatotoxicity signals have been reported in clinical trials
• ALT and AST levels generally improve with treatment, reflecting reduced hepatic steatosis

12. Related Peptides

See also: Semaglutide, Tirzepatide, Retatrutide, Mazdutide (IBI362)

13. References

1. [1] Day JW, Ottaway N, Patterson JT, et al. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. DOI PubMed
2. [2] Pocai A, Carber PE, Waring JF, et al. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. DOI PubMed
3. [3] Habegger KM, Heppner KM, Geary N, et al. (2010). The metabolic actions of glucagon revisited. Nat Rev Endocrinol. DOI PubMed
4. [4] Ambery P, Parker VE, Sherwin P, et al. (2018). MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes. Lancet. DOI PubMed
5. [5] Tillner J, Pober M, Gerlach S, et al. (2019). A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab. PubMed
6. [6] Brandt SJ, Gotz A, Tschop MH, Muller TD (2018). Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides. PubMed
7. [7] Sanyal AJ, Castera L, Wong VW (2023). Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. PubMed
8. [8] Altimmune, Inc. (2024). Pemvidutide (ALT-801) MOMENTUM Phase 2 trial results. Company press release / conference presentation.
9. [9] Altimmune, Inc. (2024). Pemvidutide (ALT-801) IMPACT Phase 2 trial results in MASH. Company press release / conference presentation.
10. [10] Altimmune, Inc. (2022). Pemvidutide (ALT-801) Phase 1b clinical results. Company press release / conference presentation.
11. [11] Drucker DJ (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. DOI PubMed